OrganiGram Holdings (OGI) AI Stock Analysis

• Market Cap: C$303.76M
• Dividend Yield: N/A
• Average Volume (3M): 443.91K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.10
• Revenue Growth: 62.15%
• EPS Growth: 60.50%
• Country: CA
• Employees: 1,093
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 135,004,750
• 10 Day Avg. Volume: 209,932
• 30 Day Avg. Volume: 443,911
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$3.63
• Price Target Upside: 31.34% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): <0.01
• Revenue Forecast (FY): C$403.17M

• Rating: 54 Neutral
• Price Target: C$2.50 ▼(-9.42% Downside)

OrganiGram Holdings' strong revenue growth and market position are offset by profitability challenges and valuation concerns. Technical indicators suggest bullish momentum, but overbought conditions could lead to a pullback. Earnings call insights are positive, but operational challenges remain.

Positive Factors

Leading Canadian market position

Sustained #1 market share and category leadership (vape 20.4%, pre-roll 8.3%) indicate durable distribution, shelf presence and brand recognition across Canada. This scale supports stable wholesale contracts, bargaining power with provinces and resilience versus smaller competitors over coming quarters.

Strong revenue growth trajectory

Rapid, sustained top-line expansion shows product demand and successful commercial execution. If managed, this revenue base enables economies of scale, amortization of fixed costs and investment in capacity and R&D, improving long-term margin potential versus peers with stagnant sales.

Exclusive genetics partnership (Phylos)

Five-year exclusivity on unique autoflower genetics creates durable product differentiation across international markets. This secures proprietary SKUs, supports premium positioning in medical and recreational segments, and lowers direct product competition risk as OrganiGram scales exports.

Negative Factors

Profitability and margin pressure

Persistent negative profitability despite revenue gains suggests structural cost or pricing issues. Low gross margins limit ability to fund SG&A and capex internally, constraining reinvestment and making long-term returns to shareholders dependent on sustained margin improvement.

Weak cash conversion

Chronic negative operating cash flow undermines self-funding of capacity expansion and working capital. Reliance on external financing or asset sales increases funding risk and can dilute equity or raise leverage if positive free cash flow targets slip, affecting strategic flexibility.

Operational and regulatory execution risks

Execution hiccups (ERP integration) and delayed EU GMP certification threaten margin uplift from direct international sales. These operational and regulatory setbacks can persistently impair distribution efficiency, delay higher-margin market entry, and reduce expected benefits from capacity investments.

OrganiGram Holdings Business Overview & Revenue Model

Company Description

Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including cannabis flowers, cannabis oils, and vaporizers for civilian patients and veterans; adult use recreational cannabis under the Edison Cannabis Co., Trail Blazer, SHRED, SHRED'ems, Big Bag O' Buds, and Monjour brands; and cannabis edibles products and concentrates. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as telephone channels. Organigram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.

How the Company Makes Money

OrganiGram generates revenue primarily through the sale of its cannabis products to both wholesale and retail customers. The company’s key revenue streams include direct sales of dried flower, oils, and edibles to licensed retailers, as well as bulk sales to provincial distributors across Canada. Additionally, OrganiGram may engage in export opportunities to international markets where cannabis is legal. Significant partnerships with licensed retailers and distributors enhance its market reach and distribution capabilities, contributing to the company's earnings. Furthermore, the company may explore additional revenue avenues through product innovation and expanding its portfolio to meet evolving consumer demands in the cannabis industry.

OrganiGram Holdings Financial Statement Overview

Summary

OrganiGram Holdings shows strong revenue growth but struggles with profitability and cash flow. The balance sheet is solid with low leverage, but operational efficiency needs improvement.

Income Statement

OrganiGram Holdings has shown a positive revenue growth rate of 15.8% in the latest annual period, indicating a strong top-line performance. However, the company is struggling with profitability, as evidenced by negative net profit margins and EBIT margins. The gross profit margin is low, which suggests challenges in cost management or pricing power.

Balance Sheet

The balance sheet reflects a solid equity base with a low debt-to-equity ratio, indicating financial stability and low leverage risk. However, the return on equity is negative, highlighting inefficiencies in generating returns from shareholders' equity. The equity ratio is healthy, suggesting a strong capital structure.

Cash Flow

The cash flow statement reveals a significant challenge in generating positive cash flows, with negative operating and free cash flows. Despite a notable improvement in free cash flow growth, the company struggles to convert net income into cash, as indicated by negative operating cash flow to net income ratios.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	259.18M	259.18M	159.84M	149.21M	145.81M	79.16M
Gross Profit	9.51M	9.51M	47.52M	35.07M	31.57M	-28.40M
EBITDA	-20.55M	-20.55M	-23.59M	-207.62M	10.96M	-95.59M
Net Income	-24.76M	-24.76M	-45.44M	-229.48M	-14.28M	-130.70M
Balance Sheet
Total Assets	562.21M	562.21M	407.86M	298.45M	577.11M	554.02M
Cash, Cash Equivalents and Short-Term Investments	84.42M	84.42M	107.57M	33.86M	98.91M	183.84M
Total Debt	8.75M	8.75M	4.46M	4.72M	3.36M	4.96M
Total Liabilities	213.08M	213.08M	101.87M	26.83M	69.05M	74.21M
Stockholders Equity	349.13M	349.13M	305.99M	271.62M	508.06M	479.81M
Cash Flow
Free Cash Flow	-24.51M	-24.64M	-1.47M	-62.70M	-84.99M	-40.92M
Operating Cash Flow	-7.46M	-7.59M	3.87M	-35.80M	-36.21M	-28.59M
Investing Cash Flow	-81.20M	-82.67M	-38.77M	1.35M	44.03M	-115.11M
Financing Cash Flow	39.33M	39.33M	107.78M	-817.00K	5.33M	174.46M

OrganiGram Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.76
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:OGI, the sentiment is Negative. The current price of 2.76 is above the 20-day moving average (MA) of 2.45, above the 50-day MA of 2.32, and above the 200-day MA of 2.09, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 42.44 is Neutral, neither overbought nor oversold. The STOCH value of 25.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:OGI.

OrganiGram Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GTII	75 Outperform	C$2.71B	45.25	2.42%	―	6.18%	-28.69%
CRON	67 Neutral	C$1.40B	27.92	3.34%	―	22.20%	―
CURA	58 Neutral	C$2.96B	-7.86	-27.61%	―	-3.38%	-31.35%
OGI	54 Neutral	C$303.76M	-11.08	-7.93%	―	62.15%	60.50%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ACB	49 Neutral	C$334.55M	-5.73	-10.76%	―	23.87%	-19.57%
WEED	47 Neutral	C$630.07M	-0.62	-60.19%	―	-0.67%	58.98%

OrganiGram Holdings Corporate Events

Organigram Deepens Phylos Partnership to Secure Long-Term Cannabis Genetics Edge

Organigram Global Inc. has expanded its innovation partnership with cannabis genetics specialist Phylos Bioscience Inc. through an amended loan and product agreement that strengthens its leadership in seed-based cultivation and provides a long-term pipeline of next-generation cannabis genetics. The deal includes a new US$3 million advance, bringing Organigram’s total loan to Phylos to US$10 million, and secures priority access to Phylos’ autoflower genetics pipeline, with 30 new genetics to be delivered twice annually through 2030 for both recreational and medical markets. Organigram gains five-year exclusive rights to selected autoflower cultivars in key international markets including Canada, Australia, the UK, Germany and Israel, with the ability to add territories as it expands globally, bolstering product differentiation and supporting its entry into high-value medical markets. The agreement is expected to enhance operational security, consistency and scalability in cultivation, while giving Organigram an economic and competitive edge as the first mover deploying scientifically bred F1 hybrid seeds at commercial scale.

The most recent analyst rating on (TSE:OGI) stock is a Hold with a C$3.00 price target. To see the full list of analyst forecasts on OrganiGram Holdings stock, see the TSE:OGI Stock Forecast page.

Organigram Achieves Record Financial Results and Expands Market Leadership

Organigram reported record financial results for the fourth quarter and fiscal year 2025, with significant increases in revenue and adjusted EBITDA. The company maintained its leadership in the Canadian cannabis market and expanded its international sales. Notable achievements include the acquisition of Motif Labs and Collective Project, advancements in genomics R&D, and a record harvest. However, potential challenges arise from U.S. legislative changes affecting hemp-derived THC products, which may impact Organigram’s operations in the U.S.

The most recent analyst rating on (TSE:OGI) stock is a Hold with a C$2.50 price target. To see the full list of analyst forecasts on OrganiGram Holdings stock, see the TSE:OGI Stock Forecast page.

Organigram Holdings Appoints New CEO to Drive Global Expansion

Organigram Holdings has appointed James Yamanaka, former Global Head of Strategy at British American Tobacco, as its new CEO, effective January 15, 2026. Yamanaka’s extensive experience in strategy and management is expected to bolster Organigram’s global aspirations, leveraging his track record of driving international growth and transforming businesses to enhance the company’s position in the cannabis industry.

The most recent analyst rating on (TSE:OGI) stock is a Hold with a C$2.50 price target. To see the full list of analyst forecasts on OrganiGram Holdings stock, see the TSE:OGI Stock Forecast page.

Canadians Call for Modernized Cannabis Policies to Boost Economy

Organigram Global Inc. has released polling data indicating that a majority of Canadians believe the federal government should modernize its cannabis policy, viewing the legal cannabis industry as a significant economic opportunity. The poll suggests that Canadians want the government to support job creation and innovation in the cannabis sector, reduce excise taxes for legal producers, and combat the illicit market. The findings highlight a shift in public perception, with cannabis now seen as a mainstream and integral part of Canada’s economic landscape, contributing significantly to GDP and employment.

The most recent analyst rating on (TSE:OGI) stock is a Hold with a C$2.50 price target. To see the full list of analyst forecasts on OrganiGram Holdings stock, see the TSE:OGI Stock Forecast page.

Organigram Extends CEO’s Tenure Amid Ongoing Search

Organigram Global Inc. has announced that CEO Beena Goldenberg will extend her tenure until November 30, 2025, to facilitate the completion of the company’s CEO search process. The board is pleased with the progress in finding a leader aligned with the company’s strategic vision and growth objectives. Goldenberg will continue to oversee daily operations, ensuring continuity and momentum across business lines, while the company remains focused on delivering key priorities and creating long-term shareholder value.

The most recent analyst rating on (TSE:OGI) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on OrganiGram Holdings stock, see the TSE:OGI Stock Forecast page.